Point72 Asset Management
SGMT icon

Point72 Asset Management’s Sagimet Biosciences SGMT Stock Holding History

Point72 Asset Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,100
Closed -$108K – 2490
2024
Q4 		$108K Sell
24,100
-50,100
-68% -$254K ﹤0.01% 1957
2024
Q3 		$206K Buy
+74,200
New +$229K ﹤0.01% 1783

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management's SGMT Position: Q1 2026 in Review

Point72 Asset Management increased its Sagimet Biosciences (SGMT) stake by 6.7% in Q1 2026, buying an estimated $65.4K and bringing the position to 187,564 shares worth $980K. The position accounts for ﹤0.01% of the portfolio, ranked #2770.

Point72 Asset Management first reported a position in SGMT in Q1 2024 and has held it in 7 quarters since. The position peaked at $14.5M in Q1 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Point72 Asset Management held 187,564 shares of Sagimet Biosciences worth $980K as of Q1 2026.
  • Point72 Asset Management bought 11,734 Sagimet Biosciences shares in Q1 2026, an estimated $65.4K.
  • Sagimet Biosciences made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2770 holding.
  • Point72 Asset Management first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 7 quarters since.
  • Point72 Asset Management's Sagimet Biosciences position peaked at $14.5M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.